Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sterubin is a **flavanone**—specifically, 7-methoxy-3',4',5-trihydroxyflavanone—extracted from Yerba Santa (Eriodictyon californicum), a plant native to California[3][2][1]. It has significant neuroprotective, anti-inflammatory, antioxidant, and iron-chelating properties demonstrated primarily in preclinical models of Alzheimer's disease and Parkinson's disease[1][2][4][5][6][7]. Sterubin acts to protect nerve cells by sustaining glutathione levels, preventing production of damaging reactive oxygen species, blocking regulated cell death (oxytosis and possibly ferroptosis), promoting Nrf2 and ATF4 signaling pathways (crucial for antioxidant response and protection against oxidative stress), and displaying a potent anti-inflammatory effect on microglia (brain immune cells)[6][2][1][5]. It has also shown the ability to inhibit monoamine oxidase B (MAO-B), reduce neuroinflammatory markers (TNF-α, IL-1β, IL-6, NF-kB), and improve dopamine and serotonin homeostasis[5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sterubin.